Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4619 Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study

Introduction: Radioligand therapy with lutetium-177 labelled somatostatin receptor (SSTR) agonists (177Lu-DOTATATE or 177Lu-DOTATOC) showed limited response rate and durability. The novel SSTR antagonist DOTA-LM3 labelled with terbium-161, which co-emits conversion and Auger electrons in addition to β- particles, potentially increasing tumour doses and offering a more effective treatment for micro metastases.

Conference:

Presenting Author: Fricke J

Authors: Fricke J, Westerbergh F, McDougall L, Christ E, Nicolas G,

Keywords: Radionuclide therapy, PRRT, Auger electrons, Conversion electrons, Terbium-161, radiolabelled somatostatin antagonist, neuroendocrine tumour,

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4533 Receptor radionuclide therapy with 177Lu-DOTATOC (177Luedotreotide or 177Lu-octreotide) in SSTR positive patients: A multicentre, prospective, phase II trial

Introduction: For advanced G1-G2 GEP-NET patients, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE can be recommended. However, there are several SSTR-positive tumours for which PRRT has previously shown efficacy that are not currently covered by the indications for 177Lu-DOTATATE in Italy and, therefore, cannot benefit from it. Less used and studied is the 177Lu-DOTATOC. This is a radiopeptide with excellent safety and efficacy profile in PRRT and certainly not lower than 177Lu-DOTATATE.

Conference:

Presenting Author: Sansovini M

Authors: Sansovini M, Nicolini S, Grassi I, Marini I, Matteucci F,

Keywords: Lu-dotatoc, Radiopharaceutical Therapy Factory, SSTR positive tumour,

#3566 177-Lu-DOTATATE in 382 patients with somatostatin receptor–positive advanced tumors: Real-world data from the SEPTRALU registry

Introduction: NETTER-I and ERASMUS clinical trials have led to Lutetium177-DOTATATE (Lu177) approval in Spain.

Conference:

Presenting Author: Mitjavila M

Authors: Mitjavila Casanovas M, Pubul V, Belló P, García-Burillo A, Arbizu J,

Keywords: 177Lu-DOTATATE, SSTR-positive, efficacy, safety,